Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now

Published July 29, 2026 · Category: Finance

Overview

Shares of Revolution Medicines (NASDAQ: RVMD), a clinical-stage drugmaker, have gained 132% this year, easily outpacing the returns of leading pharmaceutical companies such as Eli Lilly (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), and AbbVie (NYSE: ABBV). The question now is whether Revolution Medicines can keep the momentum going. Let's find out whether there is more upside ahead.

First, let's give credit where credit is due. Revolution Medicines is trying to revolutionize the oncology market, and it might just pull it off. The company is developing drugs that target cancer-driving proteins once considered "undruggable," offering the potential to precisely block the genetic errors that fuel tumors and create new treatment options for patients with hard-to-treat cancers.

Image source: Getty Images.

Details

Continue reading

Source

Originally published at www.fool.com.

Related Articles

• Stocks and bonds see wild ‘Fed Day’ swings as Wall Street’s ‘crash cushion’ evaporates
• Here are the last times the Dow dropped by 1,000 points and what happened next
• Rising Part D premiums could drive more people into Medicare Advantage plans